A treatment strategy to mitigate the adverse effect of pretransplant mogamulizumab on post-transplant clinical outcome in patients with aggressive ATL

Br J Haematol. 2024 Feb;204(2):e25-e27. doi: 10.1111/bjh.19231. Epub 2023 Dec 6.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Humans
  • Iatrogenic Disease
  • Leukemia-Lymphoma, Adult T-Cell* / drug therapy
  • Treatment Outcome

Substances

  • mogamulizumab
  • Antibodies, Monoclonal, Humanized